Skip to content

Nucleotide Protein -3 in Epileptic Children

Biochemical Role of Nucleotide Protein -3 That Activate the Interleukin-1B in Epileptic Children

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04219930
Enrollment
80
Registered
2020-01-07
Start date
2020-02-01
Completion date
2020-12-01
Last updated
2020-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy in Children

Keywords

Epilepsy, Children, NLRP3, Interleukin B1, Nuclear Factor-Kappa B

Brief summary

Epilepsy is one of common serious neurological malfunction, characterized by recurrent unprovoked seizures. It always accompanied with multitude of complications as cognitive, behavioral, and psychiatric disorders. Experimental studies and clinical evidence obtained in animal models of epilepsy and human brain specimen from various drug-resistant forms of epilepsy show the activation of the innate and adaptive immunity mechanisms and the induction of the associated inflammatory processes in the epileptogenic foci.

Detailed description

Epilepsy affects approximately 1% of the world population. Lifetime prevalence of childhood and adolescence epilepsy (children \<18 years) in Upper Egypt was 9.7/1000, with higher prevalence among children \<12 years (10.8/1000). There is a clear cause for epilepsy in only a minority of the cases, while in up to70% of all case of epilepsy in adults and children, no cause can be discovered. Some of the main causes of epilepsy include: Low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, infections such as meningitis or encephalitis, stroke or any other type of damage to the brain. A role of inflammatory molecules in the generation of seizures had been first investigated when selected anti-inflammatory treatments, in particular, steroids, immuno-globulins, and adrenocorticotropic hormone (ACTH), were shown to control seizures in pediatric epilepsies refractory to conventional anticonvulsive drugs. In addition, specific epileptic disorders have been associated with the presence of neuronal antigen-directed antibodies in plasma or cerebrospinal fluid (CSF). A nucleotide-binding oligomerization domains (NODs) are cytosolic proteins that include key regulators of apoptosis and pathogen resistance in mammals and plants. A large number of NODs contain leucine-rich repeats (LRRs), hence referred to as NOD-LRR proteins. The NLRP3 gene provides instructions for making a protein called cryopyrin. Cryopyrin is a member of a family of proteins called nucleotide-binding domain and leucine-rich repeat containing (NLR) proteins. NLR family have two common features: the first is a nucleotide-binding oligomerization domain which is bound by ribonucleotide-phosphates (rNTP) and is important for self-oligomerization. The second is a C-terminal leucine-rich repeat, which serves as a ligand-recognition domain for other receptors (e.g. Toll like receptor (TLR)) or microbial ligands, while NLRP3 has been identified in microglial cells.

Interventions

DIAGNOSTIC_TESTExpression of nucleotide protein -3

Expression of nucleotide protein -3 will be measured in serum by ELISA

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
2 Years to 17 Years

Inclusion criteria

* Epileptic children in Assiut university hospital, pediatric department, neurology unit.

Exclusion criteria

* Children with other chronic disease such as liver, kidney or heart disease * patient who have apparent infection

Design outcomes

Primary

MeasureTime frameDescription
The mean difference of nucleotide protein -3 inflammatory marker expression in epileptic children and controlsBaselinebetter understanding the role of inflammation in pathogenesis of epilepsy in children

Contacts

Primary Contactreham elmahdy
reham.elmahdy@aun.edu.eg+201002714637

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026